Clement Dana, Miron L, Marinca M
Clinica de Oncologie, Spitalul Clinic Judeţean de Urgenţă "Sf. Spiridon", Iaşi.
Rev Med Chir Soc Med Nat Iasi. 2007 Oct-Dec;111(4):856-63.
There is much debate whether the choice of management for elderly patients with locally advanced, inoperable NSCLC with good performance status (PS) should be made entirely on terms of age.
We compared the results of chemotherapy (CT), radiotherapy (RT) and chemoradiotherapy (CT-RT) of the elderly with those of younger patients, and studied predictive factors for survival in these age groups. 231 patients with advanced NSCLC were included in this study, being grouped by age: > 65 years (148p, 64.1%) versus < 65 years old (83p, 35.9%). Univariate analysis and Cox regression models were used to assess significance of variables for prediction of survival.
Mean overall survival (OS) for the whole group was 11.48 months (median 9.0 months); no significant difference in median OS was found between elderly and younger patients (11.55 vs. 11.65 months, p = 0.537). Univariate analysis revealed significant survival benefits in both age groups as per weight loss < 5%, absence of comorbidities, earlier clinical stage, high initial Hb levels, longer time-to-progression (TTP) and good PS. Treatment type had different survival impact on the age groups; best median survival in patients > 65 years (14.0 months) was obtained by CT alone, while patients < 65 years benefited more (13.35 months) from sequential CT-RT. Logistic regression model identified 5 variables to be significant for survival in all patients: PS, extent of disease, hemoglobin (Hb), TTP and age. When applied to the elderly group, only 4 variables had predictive value: extent of disease, Hb, TTP and presence of comorbidities. Treatment toxicity did not differ significantly between age subsets, except for renal toxicity, which was greater in elderly patients. Age should not be a choice-limiting item for the treatment of advanced NSCLC.
An active therapeutic approach, such as chemotherapy, can be feasible, effective and well tolerated in selected elderly NSCLC patients with a good PS and no associated comorbidities.
对于身体状况良好(PS)的局部晚期、无法手术的老年非小细胞肺癌(NSCLC)患者,治疗方案的选择是否应完全基于年龄存在诸多争议。
我们比较了老年患者与年轻患者化疗(CT)、放疗(RT)及放化疗(CT-RT)的结果,并研究了这些年龄组生存的预测因素。本研究纳入了231例晚期NSCLC患者,按年龄分组:>65岁(148例,64.1%)与<65岁(83例,35.9%)。采用单因素分析和Cox回归模型评估变量对生存预测的显著性。
全组平均总生存期(OS)为11.48个月(中位数9.0个月);老年患者与年轻患者的中位OS无显著差异(11.55对11.65个月,p = 0.537)。单因素分析显示,在两个年龄组中,体重减轻<5%、无合并症、临床分期较早、初始血红蛋白(Hb)水平较高、疾病进展时间(TTP)较长及PS良好均有显著的生存获益。治疗类型对不同年龄组的生存影响不同;>65岁患者单独化疗的最佳中位生存期为14.0个月,而<65岁患者序贯CT-RT的获益更大(13.35个月)。Logistic回归模型确定了5个对所有患者生存有显著意义的变量:PS、疾病范围、血红蛋白(Hb)、TTP和年龄。应用于老年组时,只有4个变量具有预测价值:疾病范围、Hb、TTP和合并症的存在。除肾毒性在老年患者中更大外,各年龄亚组的治疗毒性无显著差异。年龄不应成为晚期NSCLC治疗的限制选择因素。
对于PS良好且无相关合并症的老年NSCLC患者,积极的治疗方法如化疗可能是可行、有效且耐受性良好的。